Evidence map›Paper›PMID 24928201›Full record

ArticleNeurotoxicology2014

4R-cembranoid protects against diisopropylfluorophosphate-mediated neurodegeneration.

P A Ferchmin, Myrna Andino, Rebeca Reyes Salaman, Janaina Alves, Joyce Velez-Roman, Brenda Cuadrado, Marimeé Carrasco, Wilmarie Torres-Rivera, Annabell Segarra, Antonio Henrique Martins and 2 more

Open access · greenAbstract read
In one paragraph

Article in Neurotoxicology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
7.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Recovery of Cembratrien-Diols from Waste Tobacco (Molecules (Basel, Switzerland) · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Phytochemicals derived fromFrontiers in pharmacology · 2024
    Review
  7. Memantine has a nicotinic neuroprotective pathway in acute hippocampal slices after an NMDA insult.Toxicology in vitro : an international journal published in association with BIBRA · 2022
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

P A FerchminDepartment of Biochemistry, Universidad Central del Caribe School of Medicine, Bayamón, PR 00960, USA. Electronic address: ferchmin@gmail.com.
Myrna AndinoDepartment of Biochemistry, Universidad Central del Caribe School of Medicine, Bayamón, PR 00960, USA.
Rebeca Reyes SalamanDepartment of Biochemistry, Universidad Central del Caribe School of Medicine, Bayamón, PR 00960, USA.
Janaina AlvesDepartment of Biochemistry, Universidad Central del Caribe School of Medicine, Bayamón, PR 00960, USA.
Joyce Velez-RomanDepartment of Pharmacology, University of Puerto Rico Medical Sciences Campus, San Juan, PR 00936, USA.
Brenda CuadradoDepartment of Biochemistry, Universidad Central del Caribe School of Medicine, Bayamón, PR 00960, USA.
Marimeé CarrascoDepartment of Biochemistry, Universidad Central del Caribe School of Medicine, Bayamón, PR 00960, USA.
Wilmarie Torres-RiveraDepartment of Biochemistry, Universidad Central del Caribe School of Medicine, Bayamón, PR 00960, USA.
Annabell SegarraDepartment of Pharmacology, University of Puerto Rico Medical Sciences Campus, San Juan, PR 00936, USA.
Antonio Henrique MartinsDepartment of Biochemistry, Universidad Central del Caribe School of Medicine, Bayamón, PR 00960, USA.
Jae Eun LeeRTRN Data Coordinating Center, Jackson State University, Jackson, MI 39204, USA.
Vesna A EterovicDepartment of Biochemistry, Universidad Central del Caribe School of Medicine, Bayamón, PR 00960, USA.
Central University of the Caribbean · PRUniversity of Puerto Rico, Medical Sciences Campus · PRJackson State University · US

Funding

STEERING COMMITTEEU54MD008149 · NIMHD · MOREHOUSE SCHOOL OF MEDICINE · PI OFILI, ELIZABETH O. · 2012 to 2018
$21.1M
UNIVERSIDAD CENTRAL DEL CARIBE BIOMEDICAL RESEARCH CENTERSG12MD007583 · NIMHD · UNIVERSIDAD CENTRAL DEL CARIBE · PI FERNANDEZ, DIANA MARIA · 2012 to 2016
$8.4M
Regulation of synaptic vesicle mobilization,priming and recycling by complexinU54NS083924 · NINDS · UNIVERSIDAD CENTRAL DEL CARIBE · PI BYKHOVSKAIA, MARIA · 2013 to 2015
$4.3M
PROTECTION AGAINST ORGANOPHOSPHATE NEUROTOXINS BY TOBACCO CEMBRANOIDSU01NS063555 · NINDS · UNIVERSIDAD CENTRAL DEL CARIBE · PI FERCHMIN, P. A. · 2008 to 2010
$2.0M
NIMHD NIH HHS 8G12MD007583NIMHD NIH HHS G12 MD007583NIMHD NIH HHS U54 MD008149NIMHD NIH HHS U54MD008149NINDS NIH HHS 1U54NS083924-01NINDS NIH HHS NINDS5U01NS063555NINDS NIH HHS U01 NS063555NINDS NIH HHS U54 NS083924
6 · The paper itself

Abstract

Many organophosphorous esters synthesized for applications in industry, agriculture, or warfare irreversibly inhibit acetylcholinesterase, and acute poisoning with these compounds causes life-threatening cholinergic overstimulation. Following classical emergency treatment with atropine, an oxime, and a benzodiazepine, surviving victims often suffer brain neurodegeneration. Currently, there is no pharmacological treatment to prevent this brain injury. Here we show that a cyclic diterpenoid, (1S,2E,4R,6R,7E,11E)-cembra-2,7,11-triene-4,6-diol (4R) ameliorates the damage caused by diisopropylfluorophosphate (DFP) in the hippocampal area CA1. DFP has been frequently used as a surrogate for the warfare nerve agent sarin. In rats, DFP is lethal at the dose used to cause brain damage. Therefore, to observe brain damage in survivors, the death rate was reduced by pre-administration of the peripherally acting antidotes pyridostigmine and methyl atropine or its analog ipratropium. Pyridostigmine bromide, methyl atropine nitrate, and ipratropium bromide were dissolved in saline and injected intramuscularly at 0.1mg/kg, 20mg/kg, and 23mg/kg, respectively. DFP (9mg/kg) dissolved in cold water was injected intraperitoneally. 4R (6mg/kg) dissolved in DMSO was injected subcutaneously, either 1h before or 5 or 24h after DFP. Neurodegeneration was assessed with Fluoro-Jade B and amino cupric silver staining; neuroinflammation was measured by the expression of nestin, a marker of activated astrocytes. Forty-eight hours after DFP administration, 4R decreased the number of dead neurons by half when injected before or after DFP. 4R also significantly decreased the number of activated astrocytes. These data suggest that 4R is a promising new drug that could change the therapeutic paradigm for acute poisoning with organophosphorous compounds by the implementation of a second-stage intervention after the classical countermeasure treatment.

Indexed as

AcetylcholinesteraseAnimalsBrain InjuriesCA1 Region, HippocampalCell DeathCholinesterase InhibitorsDiterpenesIsoflurophateMaleNeuroprotective AgentsRatsRats, Sprague-DawleySeizuresAcetylcholinesterasecembra-2,7,11-triene-4,6-diolCholinesterase InhibitorsDiterpenesIsoflurophateNeuroprotective Agents(1S,2E,4R,6R,7E,11E)-Cembra-2,7,11-triene-4,6-diolCembranoidDiisopropylfluorophosphateNeurodegenerationNeuroprotection

Identifiers

PMID24928201
PMCPMC4176603
OpenAlexW1983849928

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.